..., but they may be a little late. Mike Huckman, CNBC's biotech reporter, came on the show to talk about a potential blockbuster diabetes treatment for Eli Lilly (LLY) and its partner Amylin Pharmaceuticals(AMLN). He said the two companies are waiting for FDA approval for a once-weekly diabetes treatment called exenatide LAR, which, if approved, could be worth $1 billion in sales a year. He said ...

http://community.livejournal.com/cramermadmoney/330265.html
0 links
Published: 2 months ago (Tue, 05 May 2009 19:34:32 PDT); 5992 bytes
|